SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

被引：8

作者：

Haggenburg, Sabine ^{[1
,2
,8
]}

Hofsink, Quincy ^{[1
,2
]}

Rutten, Caroline E. ^{[1
]}

Nijhof, Inger S. ^{[3
,4
,5
]}

Hazenberg, Mette D. ^{[1
,2
,5
,6
]}

Goorhuis, Abraham ^{[7
]}

机构：

[1] Amsterdam UMC locat Univ Amsterdam, Dept Hematol, Amsterdam, Netherlands

[2] Amsterdam Inst Infect & Immun, Amsterdam UMC, Amsterdam, Netherlands

[3] Amsterdam UMC locat Vrije Univ, Dept Hematol, Amsterdam, Netherlands

[4] St Antonius Hosp, Dept Internal Med Hematol, Nieuwegein, Netherlands

[5] Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands

[6] Sanquin Res, Dept Hematopoiesis, Amsterdam, Netherlands

[7] Amsterdam UMC locat Univ Amsterdam, Ctr Trop Med & Travel Med, Dept Infect Dis, Amsterdam, Netherlands

[8] Amster dam UMC locat Univ Amsterdam, Dept Hematol, Meibergdreef 9, NL-1105 Amsterdam, Netherlands

来源：

SEMINARS IN HEMATOLOGY | 2022年 / 59卷 / 04期

关键词：

COVID-19; SARS-CoV-2; Vaccination; Immunocompromised; Hematologic malignancies; Hematology; RNA COVID-19 VACCINATION; ANTIBODY-RESPONSES; T-CELL;

D O I：

10.1053/j.seminhematol.2022.11.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3 -dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against se -vere COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effec-tiveness studies. (c) 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

引用

页码：192 / 197

页数：6

共 68 条

[31] Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination
Kato, Hideaki
Miyakawa, Kei
Ohtake, Norihisa
Yamaoka, Yutaro
Yajima, Satoshi
Yamazaki, Etsuko
Shimada, Tomoko
Goto, Atsushi
Nakajima, Hideaki
Ryo, Akihide
[J]. VACCINE, 2022, 40 (19) : 2652 - 2655
[32] WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community
Knezevic, Ivana
Mattiuzzo, Giada
Page, Mark
Minor, Philip
Griffiths, Elwyn
Nuebling, Micha
Moorthy, Vasee
[J]. LANCET MICROBE, 2022, 3 (03): : E235 - E240
[33] Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
Leclerc, Mathieu
Redjoul, Rabah
Le Bouter, Anne
Beckerich, Florence
Robin, Christine
Parinet, Vincent
Pautas, Cecile
Menouche, Dehbia
Bouledroua, Selwa
Roy, Lydia
Cabanne, Ludovic
Nait-Sidenas, Yakout
Harfouch, Elham
Gautier, Eric
Fourati, Slim
Maury, Sebastien
[J]. LANCET HAEMATOLOGY, 2022, 9 (05): : E318 - E321
[34] COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study
Lee, Lennard Y. W.
Ionescu, Maria C.
Starkey, Thomas
Little, Martin
Tilby, Michael
Tripathy, Arvind R.
Mckenzie, Hayley S.
Al-Hajji, Youssra
Appanna, Nathan
Barnard, Matthew
Benny, Liza
Burnett, Alexander
Cattell, Emma L.
Clark, James J.
Khan, Sam
Ghafoor, Qamar
Panneerselvam, Hari
Illsley, George
Harper-Wynne, Catherine
Hattersley, Rosie J.
Lee, Alvin J. X.
Lomas, Oliver
Liu, Justin K. H.
McCauley, Amanda
Pang, Matthew
Pascoe, Jennifer S.
Platt, James R.
Patel, Grisma
Patel, Vijay
Potter, Vanessa A.
Randle, Amelia
Rigg, Anne S.
Robinson, Tim M.
Roques, Tom W.
Roux, Rene L.
Rozmanowski, Stefan
Taylor, Harriet
Tuthill, Mark H.
Watts, Isabella
Williams, Sarah
Beggs, Andrew
Iveson, Tim
Lee, Siow M.
Middleton, Gary
Middleton, Mark
Protheroe, Andrew
Fittall, Matthew W.
Fowler, Tom
Johnson, Peter
[J]. EUROPEAN JOURNAL OF CANCER, 2022, 175 : 1 - 10
[35] Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
Li, Chunfeng
Lee, Audrey
Grigoryan, Lilit
Arunachalam, Prabhu S.
Scott, Madeleine K. D.
Trisal, Meera
Wimmers, Florian
Sanyal, Mrinmoy
Weidenbacher, Payton A.
Feng, Yupeng
Adamska, Julia Z.
Valore, Erika
Wang, Yanli
Verma, Rohit
Reis, Noah
Dunham, Diane
O'Hara, Ruth
Park, Helen
Luo, Wei
Gitlin, Alexander D.
Kim, Peter
Khatri, Purvesh
Nadeau, Kari C.
Pulendran, Bali
[J]. NATURE IMMUNOLOGY, 2022, 23 (04) : 543 - +
[36] Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Lim, Sean H.
Stuart, Beth
Joseph-Pietras, Debora
Johnson, Marina
Campbell, Nicola
Kelly, Adam
Jeffrey, Danielle
Turaj, Anna H.
Rolfvondenbaumen, Kate
Galloway, Celine
Wynn, Thomas
Coleman, Adam R.
Ward, Benjamin
Long, Karen
Coleman, Helen
Mundy, Carina
Bates, Andrew T.
Ayres, Diana
Lown, Robert
Falconer, Janlyn
Brake, Oliver
Batchelor, James
Willimott, Victoria
Al-Naeeb, Anna Bowzyk
Robinson, Lisa
O'Callaghan, Ann
Collins, Graham P.
Menne, Tobias
Faust, Saul N.
Fox, Christopher P.
Ahearne, Matthew
Johnson, Peter W. M.
Davies, Andrew J.
Goldblatt, David
[J]. NATURE CANCER, 2022, 3 (05) : 552 - +
[37] Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A.
Baillie, V
Cutland, C. L.
Voysey, M.
Koen, A. L.
Fairlie, L.
Padayachee, S. D.
Dheda, K.
Barnabas, S. L.
Bhorat, Q. E.
Briner, C.
Kwatra, G.
Ahmed, K.
Aley, P.
Bhikha, S.
Bhiman, J. N.
Bhorat, A' E.
du Plessis, J.
Esmail, A.
Groenewald, M.
Horne, E.
Hwa, S-H
Jose, A.
Lambe, T.
Laubscher, M.
Malahleha, M.
Masenya, M.
Masilela, M.
McKenzie, S.
Molapo, K.
Moultrie, A.
Oelofse, S.
Patel, F.
Pillay, S.
Rhead, S.
Rodel, H.
Rossouw, L.
Taoushanis, C.
Tegally, H.
Thombrayil, A.
van Eck, S.
Wibmer, C. K.
Durham, N. M.
Kelly, E. J.
Villafana, T. L.
Gilbert, S.
Pollard, A. J.
de Oliveira, T.
Moore, P. L.
Sigal, A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (20) : 1885 - 1898
[38] Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
Maillard, Alexis
Redjoul, Rabah
Klemencie, Marion
Wallet, Helene Labussiere
Le Bourgeois, Amandine
D'Aveni, Maud
Huynh, Anne
Berceanu, Ana
Marchand, Tony
Chantepie, Sylvain
Garcia, Carmen Botella
Loschi, Michael
Joris, Magalie
Castilla-Llorente, Cristina
Thiebaut-Bertrand, Anne
Francois, Sylvie
Leclerc, Mathieu
Chevallier, Patrice
Nguyen, Stephanie
[J]. BLOOD, 2022, 139 (01) : 134 - 137
[39] Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Malard, Florent
Gaugler, Beatrice
Gozlan, Joel
Bouquet, Lucie
Fofana, Djeneba
Siblany, Lama
Eshagh, Deborah
Adotevi, Olivier
Laheurte, Caroline
Ricard, Laure
Dulery, Remy
Stocker, Nicolas
van de Wyngaert, Zoe
Genthon, Alexis
Banet, Anne
Memoli, Mara
Ikhlef, Souhila
Sestilli, Simona
Vekhof, Anne
Brissot, Eolia
Marjanovic, Zora
Chantran, Yannick
Cuervo, Nancy
Ballot, Eric
Morand-Joubert, Laurence
Mohty, Mohamad
[J]. BLOOD CANCER JOURNAL, 2021, 11 (08)
[40] Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
Maneikis, Kazimieras
Sablauskas, Karolis
Ringeleviciute, Ugne
Vaitekenaite, Vilmante
Cekauskiene, Rita
Kryzauskaite, Lina
Naumovas, Daniel
Banys, Valdas
Peceliunas, Valdas
Beinortas, Tumas
Griskevicius, Laimonas
[J]. LANCET HAEMATOLOGY, 2021, 8 (08): : E583 - E592

← 1 2 3 4 5 6 7 →